Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Trial Profile

fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACP 001 (Primary)
  • Indications Somatotropin deficiency
  • Focus Adverse reactions; Registrational
  • Acronyms fliGHt
  • Sponsors Ascendis Pharma
  • Most Recent Events

    • 19 Jun 2019 According to an Ascendis Pharma media release, detailed data from the study will be presented at an R&D Day for the investment community on Wednesday, June 26, 2019.
    • 20 May 2019 Results presented in an Ascendis Pharma media release.
    • 20 May 2019 According to an Ascendis Pharma media release, of the 146 subjects enrolled in the trial, 143 completed dosing and 140 rolled into the ongoing enliGHten Trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top